- Record: found
- Abstract: found
- Article: not found
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell
1 ,
Enric Carcereny ,
Radj Gervais ,
Alain Vergnenegre ,
Bartomeu Massuti ,
Enriqueta Felip ,
Ramon Palmero ,
Ramon Garcia-Gomez ,
Cinta Pallares ,
Jose Miguel Sanchez ,
Rut Porta ,
Manuel Cobo ,
Pilar Garrido ,
Flavia Longo ,
Teresa Moran ,
Amelia Insa ,
Filippo De Marinis ,
Romain Corre ,
Isabel Bover ,
Alfonso Illiano ,
Eric Dansin ,
Javier de Castro ,
Michele Milella ,
Noemi Reguart ,
Giuseppe Altavilla ,
Ulpiano Jimenez ,
Mariano Provencio ,
Miguel Angel Moreno ,
Josefa Terrasa ,
Jose Muñoz-Langa ,
Javier Valdivia ,
Dolores Isla ,
Manuel Domine ,
Olivier Molinier ,
Julien Mazieres ,
Nathalie Baize ,
Rosario Garcia-Campelo ,
Gilles Robinet ,
Delvys Rodriguez-Abreu ,
Guillermo Lopez-Vivanco ,
Vittorio Gebbia ,
Lioba Ferrera-Delgado ,
Pierre Bombaron ,
Reyes Bernabe ,
Alessandra Bearz ,
Angel Artal ,
Enrico Cortesi ,
Christian Rolfo ,
Maria Sanchez-Ronco ,
Ana Drozdowskyj ,
Cristina Queralt ,
Itziar de Aguirre ,
Jose Luis Ramirez ,
Jose Javier Sanchez ,
Miguel Angel Molina ,
Miquel Taron ,
Luis Paz-Ares
Mar 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC.